Top Markets
Coin of the day
Mustang Bio, Inc. Mustang Bio, Inc.

Mustang Bio, Inc.

MBIO
株式のランク #35075
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on... Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
株価
$0.594
最終同期: 2026-08-14
時価総額
$4.50M
変化(1日)
0.00%
変化(1年)
-66.44%
US
取引 Mustang Bio, Inc. (MBIO)

カテゴリー

Mustang Bio, Inc.(MBIO)の株価履歴
終値の最高値: $0.60 (2026-08-01)

終値の最安値: $8.92K (2017-08-01)
Mustang Bio, Inc. の株価履歴(2017 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) -10.26%
2025 -87.55%
2024 -86.83%
2023 -76.52%
2022 -79.00%
2021 -45.05%
2020 -1.99%
2019 18.38%
2018 -73.75%
2017 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE